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provides beneﬁ ts at other fracture sites as shown in the postmenopausal pivotal trial 
FREEDOM, the ICER reduces to c19,726. a probabilistic SA showed that denosumab 
was a cost-effective option for a willingness to pay >c60,000. CONCLUSIONS: 
Denosumab prevents vertebral fractures in patients with PrCa receiving ADT and is 
cost-effective versus no treatment. Vertebral fractures signiﬁ cantly reduce quality of 
life and since there is no other licensed treatment in Sweden, denosumab represents 
an important option in PrCa at commonly accepted CE thresholds in Sweden.
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OBJECTIVES: Median age of newly diagnosed non-small cell lung cance (NSCLC) is 
70 years (with 1/3 older than 75 years) and elderly are more vulnerable to chemo-
therapy. In this population, weekly gemcitabine and docetaxel or erlotinib are both 
active in advanced NSCLC treatment. The GFPC0504 randomized prospective phase 
2 study assess in ﬁ t elderly patients with advanced NSCLC, efﬁ cacy of weekly chemo-
therapy followed by erlotinib if progression (Arm A) versus erlotinib followed by 
chemotherapy if progression (arm B). The main objective of this study was time before 
second progression, secondary objective was overall survival. The objective of this 
study is to assess the cost-effectiveness of erlotinib in ﬁ rst-line treatment of NSCLC 
in ﬁ t elderly patients. METHODS: Outcomes (PFS and overall survival) and direct 
medical costs until second progression (from the third-party payer perspective) were 
prospectively collected. Costs after second progression and health utilities (based on 
disease states and grade 3–4 toxicities) were derived from the literature. RESULTS: 
For respectively 48 and 51 patients randomized respectively in arm a and B, PFS were 
6.4 and 5.2 months, overall survival were 9.2 and 7.9 months; mean Qualy and mean 
direct costs (euros value 2010) were respectively c0.434 ± c0.394 and c26,297 ± 
c25,297 and c0.471 ± c0.451 and c25,948 ± c18,206. Acceptability curve will be 
presented at the meeting. CONCLUSIONS: In this population of ﬁ t ederly patients, 
erlotinb in ﬁ rst line, followed by chemotherapy if progression appears as dominant 
compare to chemotherapy followed by erlotinib if progression.
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OBJECTIVES: Sorafenib and sunitinib are approved for patients with advanced or 
metastatic renal cell carcinoma after INF-a or IL-2 therapy failure or intolerance, with 
PS 0-1 and without CNS metastasis in deﬁ ned cancer centers in the Czech Republic; 
sunitinib is reimbursed for ﬁ rst-line therapy in mRCC patients of good or intermediate 
risk. METHODS: We assessed the cost of sunitinib and sorafenib in patients treated 
in comprehensive cancer center and prepared cost-effectiveness analysis (CEA) to 
compare our data to CEA submitted by manufacturers to Czech authority (SUKL = 
State Institute for Drug Control) in reimbursement proceedings between 2008 and 
2010. (1c = 26CZK). RESULTS: CEA of sunitinib submitted to SUKL was based on 
cost of pharmacotherapy and clinical data of Motzer et al. study (NEJM 2007; time 
to PD: sunitinib 11 months, INF-a 5 months; duration of PD to death 6 months). Cost 
per progression-free year (PFY) was 324144CZK/12467c in manufacturer’s analysis, 
CZK867,946CZK/c33,383 in SUKL analysis (after INF-a cost reduction and costs 
after PD removal) and CZK2,304,914/c88,651 in our analysis (cost and effects of 
sunitinib based on our results; INF-a data were assumed identically). CEA of sorafenib 
was performed for patients after cytokine intolerance or failure (Escudier et al.; NEJM 
2007) in comparison with sunitinib (70% pts) or BSC (30% pts). The cost per PFY 
was CZK965,726/c37,143 in manufacturer’s analysis. Although sorafenib was 
cheaper alternative according to our results, time to progression was shortened by 18 
days (ICER CZK516,820/c1,9878 per PFY). CONCLUSIONS: The cost per PFY in 
sunitinib was seven times lower in manufacturer’s analysis than in CEA based on real 
data from cancer center. We assume that this was mainly caused by shorter time of 
pharmacotherapy in original study (6 vs. 11 months in our data). CEA of sorafenib 
demonstrated lower costs and effects in our analysis, because the signiﬁ cance of 
comparator (70% pts sunitinib) was underestimated in manufacturer’s analysis.
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OBJECTIVES: The aim of a sympathetic blockade is to improve the analgesic 
response, diminish the opioid consumption, reduce the adverse effects from opioides, 
and get efﬁ ciency of costs related to treatment. We analyzed the cost-effectiveness of 
Splanchnic Nerves Blockade (SNB) versus drug therapy in patients with cancer and 
visceral pain at the upper abdomen. METHODS: A cost-effectiveness analysis was 
conducted within a retrospective, follow-up study in patients >18 years with cancer 
and visceral pain. Using medical records, we assessed patients that underwent a SNB 
between March 2005 and December 2009. We evaluated the visual analog pain scale 
(VAS), Karnofsky performance scale (KPS), and medical direct costs. The measures 
were evaluated before and after (1, 2, 3, 6, 9, and 12 months) the procedure. Cost 
methodology was calculated trough cost of illness and microcosting technique, to get 
the incremental cost-effectiveness ratio (ICER). RESULTS: Sixty-ﬁ ve patients were 
treated with SNB and 19 with drug treatment-WHO analgesic ladder steps (mean age 
52.7 ± 12.9 and 54 ± 12.9, respectively). Basal characteristics were not different 
between them. VAS scores diminished in both arms, but at repeated measures ANOVA 
patients on SNB had better pain control (P < 0.05) and higher KPS (P < 0.05). The 
mean cost per patient in 1-year follow-up for the drug treatment group was $7512 
MXP (CI 95% $1587–$13,436 MXP) and $5433 (CI 95% $5114–$5752) for SNB. 
The effectiveness measure was 80% for SNB versus 20% for the drug treatment group, 
respectively. The ICER obtained was negative (−$3526 MXP, IC 95% −5860 to 
−1191), favoring the SNB as a cost-saving alternative. CONCLUSIONS: SNB showed 
to be less costly and more effective than drug treatment alone. However, when a sensi-
tive analysis (bootstrap methodology) was conducted, the sample size was not power-
ful enough for a precise CE estimate.
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OBJECTIVES: Pharmacoeconomic analysis of direct medical costs of mCRC therapy 
using XELOX/FOLFOX4, XELOX + BV/FOLFOX4 + BV. METHODS: Costs of 
diagnosis, medical services, and hospitalization were based on the price list for diag-
nostic and therapeutic procedures of Cancer Research Center n.a. N.N.Blokhin 
RAMS. The medical services patient should receive during the treatment and the 
frequency of their appointments were taken from the standards of medical care for 
patients with colon and rectum cancer. Cost analysis of anticancer drugs (16 courses 
of XELOX/XELOX + BV, 24 courses of FOLFOX4/FOLFOX4 + BV) and related 
drugs were based on the information about maximum selling import prices, registered, 
and entered into the State Register of prices of vitally essential drugs. The cost of other 
drugs was based on a database of retail prices for drugs in pharmacies, which was 
subsequently reduced by trade discount. RESULTS: In was calculated that the cost of 
diagnosis was 16,757 rubles and the medical services—379,815 rubles. The mCRC 
therapy as a ﬁ rst line by XELOX was 1,172,731 rubles and by XELOX + 
BV—2,526,110 rubles; by FOLFOX4—1,487,627 rubles and by FOLFOX4 + 
BV—2,843,558 rubles. The cost saving in applying the regime XELOX compared to 
FOLFOX4 regime amounted to 314,896 rubles. In applying the regime of XELOX in 
combination with BV in comparison with the regime of FOLFOX4 in combination 
with BV amounted to 317,448 rubles. Sensitivity analysis showed that the decrease 
and increase of the cost of capecitabine and bevacizumab in 20% for XELOX/XELOX 
+ BV does not exceed the cost of regimes FOLFOX/FOLFOX4 + BV. CONCLU-
SIONS: From the pharmacoeconomic point of view, the most optimal is the use of 
XELOX and XELOX + BV regimes because of lower costs for neutropenia treatment, 
associated with an increased risk of infectious complications, as well as with a large 
number of hospitalization days.
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OBJECTIVES: To calculate the incremental cost-effectiveness of docetaxel-adriami-
cine-cyclophosphamide (TAC) against adriamicine- cyclophosphamide-5 ﬂ ourouracil 
(FAC) in treatment of breast cancer in south of Iran. METHODS: A double blind 
study was applied on a cohort of 100 patients suffering from breast cancer with node-
positive in the radiotherapy center of Namazi Hospital, Shiraz, Iran. The European 
organization for research and treatment of cancer questionnaire (EORTC QLQ-C30) 
was used for the measuring of quality of life at the ﬁ rst and last session of chemo-
therapy cycle. Third-party payer perspective was applied for costing side of evaluation. 
At last, two-way sensitivity analysis was used for ensuring the robustness of the results. 
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RESULTS: In spite of the same quality of life score at the ﬁ rst session of chemotherapy 
(74.5 out of 100), after ﬁ nishing the chemotherapy cycle, patients in TAC arm had 
the lower score of QOL (64 in TAC vs. 68 in FAC) and higher range of toxicity and 
their medical costs were higher as well (the average costs in TAC was 391,176,968.2 
Rials vs. 2,427,775.2 in FAC). ICER was negative that showed the dominant result 
for FAC comparing with TAC. CONCLUSIONS: It seems that because of the short 
horizon of the study, TAC regimen had the worse impact on the patient’s quality of 
life during the chemotherapy cycle because of more side effects than FAC. It is believed 
that there is need for other studies with longer time horizons and speciﬁ c attention to 
the effects of these treatments on survival and quality of life.
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OBJECTIVES: Breast cancer is known to be one of the leading causes of death among 
the female population. Preventive measures may provide an economic and outcome 
advantage by reducing treatment costs and increasing survival. The objective of this 
study was to evaluate the cost-effectiveness of a breast cancer vaccine versus current 
standard treatments. METHODS: TreeAge software was used to calculate the cost-
effectiveness. a decision tree was constructed for different probabilities of success and 
failure for the vaccine versus standard treatment. Costs and outcomes (life-years saved) 
ranges were obtained from published clinical trials. The vaccine effectiveness was 
projected from animal studies, with human clinical trials expected within a year. The 
range of effectiveness of the vaccine was considered between 30% and 90% with a 
baseline at 80%. The costs included for standard treatments ranged from $20,000 to 
$45,000 and the cost of the vaccine was assumed at $450 for three doses; therefore, 
the cost for vaccine ranged from $300 to $2000 depending on the number of doses. 
The incremental cost-effectiveness ratios were calculated from the range of costs and 
outcomes. Sensitivity analyses were performed to determine the robustness of the 
ﬁ ndings. RESULTS: Vaccination was found to be a potentially cost-effectiveness 
option with an ICER of 2384.146 relative to standard treatment. The incremental 
effectiveness was 8.2 life-years saved. The highest cost-effectiveness of the vaccine was 
at 90% success and a cost of not more than $1000 per individual. Sensitivity analyses 
indicated that the vaccine remained cost-effective over the range of model parameters. 
CONCLUSIONS: The breast cancer vaccine was projected to be the most cost-
effective treatment option in this analysis. It is expected that better screening for breast 
cancer vaccine patient candidates will be available in the future.
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OBJECTIVES: For the ﬁ rst time in a modern Russian economic conditions, it has been 
made pharmacoeconomics trial (PE) uses Russian generic of paclitaxel (Paclitaxel-Lens 
[PL]) in comparison with original drug (Taxol (T)) at chemotherapy (ChT) in a 
monomode for 2nd line of metastatic breast cancer (MBC) in real clinical practice. 
METHODS: It has been provided retrospective comparative nonrandomized clinical 
trial which have been included 70 patients for 35 patients of each group (PL or T) 
after analysis of 148 case records. RESULTS: At the analysis of effectively treatment 
MBC in group of the patients who have received T, the partial remission (PR, 28.5% 
against 10%) statistically signiﬁ cantly has been more often reached. At the analysis 
of safety, it has been shown that in group of the patients who have received PL, 
statistically signiﬁ cantly has been more often ﬁ xed hepatotoxicity (23.3% against 
3.8%) and an anemia (19.2% against 3.5%). In group of the patients who have 
received T, statistically signiﬁ cantly has been more often ﬁ xed arthralgia/ myalgia 
(29.8% against 0%). Total direct costs (DC) in group of patients with T also there 
were above, than in group of PL, namely $10,727 and $9765 accordingly. Calculation 
of efﬁ ciency of expenses has shown that treatment of MBC by T more expensive and 
more effective, than treatment by PL. CONCLUSIONS: Thus, as a result of research, 
it has been established that: 1) Applying of T was more (from 7% to 11%) expensive, 
than PL, but gave the PR is much more often; 2) The alternative scenario and the 
sensitivity analysis shown to choose conditions when application of compared drugs 
will be economically more expedient; and 3) Thus, it is necessary to take into consid-
eration, what application of PL was more often accompanied by hepatotoxicity and 
anemia, like arthralgia/ myalgia after using of T.
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OBJECTIVES: To determine and compare the cost-effectiveness of Bev + Pac + Car 
versus Pem + Cis regimens in the treatment of patients with adenocarcinoma non-
squamous NSCLC from a Polish Public Payer’s perspective. METHODS: Efﬁ cacy and 
safety of 15 mg of bevacizumab + 200 mg/m2 of paclitaxel + 6 mg/mL/min of carbo-
platin versus 500 mg/m2 of pemetrexed and 75 mg/m2 of cisplatin was assessed based 
on a systematic review performed for both therapies according to evidence-based 
medicine principles. A cost-effectiveness analysis was performed with a lifetime (5 
years) horizon and the National Health Fund perspective. a three state (progression-
free, progression, death) Markov model was developed. Costs of 1st and 2nd line 
therapy, administration and monitoring, adverse events treatment, and palliative care 
were included. Sensitivity analyses testing the inﬂ uence of length of time horizon, 
probability of progression, utilities, discounting rates, cisplatin dose, and the length 
and costs of 2nd line therapy were performed. RESULTS: Bev + Pac + Car results in 
0.21 life-years gained per patient when compared to Pem + Cis in the treatment of 
patients with adenocarcinoma non-squamous NSCLC. The additional cost per patient 
was 18,840 pln (1 EURO = 4.1PLN) over patient’s lifetime when Bev + Pac + Car 
was used instead of Pem + Cis regimen. The incremental cost-effectiveness ratio (ICER) 
was at an acceptable 91,216 pln. The sensitivity analyses demonstrated that the dura-
tion of 2nd line treatment (assumption of 2nd line treatment continuation for more 
than six cycles) considerably inﬂ uenced the ICER (1,198 pln). Other sensitivity analy-
ses conﬁ rmed the base-case results, proving conclusions’ robustness. CONCLUSIONS: 
Based on this modeling analysis, 1st line Bev + Pac + Car therapy is a clinically superior 
and cost-effective treatment for patients with adenocarcinoma non-squamous NSCLC 
when compared to chemotherapies such as Pem + Cis.
PCN92
PHARMACOEPIDEMIOLOGICAL AND PHARMACOECONOMIC 
EVALUATION OF OXALIPLATIN IN PALLIATIVE CHEMOTHERAPY OF 
METASTATIC COLORECTAL CANCER (MCCR)
Kolbin A1, Orlova R2, Pavlysh A3, Llivshits M1
1Saint Petersburg State University, Saint Petersburg, Russia; 2Saint Petersburg Medical 
Academy of Postgraduate Education, Saint Petersburg, Russia; 3Saint Petersburg City Clinical 
Oncology Dispensary, Saint Petersburg, Russia
The problem of original drugs substitution on generics presents in the Russian clinical 
practice due to rational expenditures allocation. Pharmaceutical bioequivalence of 
generic should be conﬁ rmed by therapeutic one. Only after such kind of conﬁ rmation, 
the mentioned substitution could be made in different segments of doctors’ practice 
especially in anticancer chemotherapy. OBJECTIVES: To evaluate the clinical-eco-
nomic interchangeability of the original oxaliplatin Eloxatine (EL) and local generic 
Exorum (EX) in the chemotherapy of mCCR. METHODS: The retrospective clinical-
economic analysis of FOLFOX scheme for chemotherapy of mCCR with EL and EX 
in the real practice has been performed. Fifty case histories (23 with using of EL, 
27—EX, was used nomogram of Altman’s) were studied. The calculation of direct 
cost and cost-effectiveness ratio (CER) based on “partial regress + stabilization” 
parameter no less than 80% has been performed. RESULTS: For achievement of equal 
efﬁ cacy EL had less number of chemotherapy cycles and total dosage compared with 
EX (5,0 and 7,3; 670 mg and 900 mg, respectively). Adverse effects were more fre-
quent in EX versus EL (59 and 38, respectively) and caused additional costs and 
prolonged hospitalization (9 days/patient compared to EL group). The utilitarian EX 
program cost per patient was less compared to EL by 7,7%. In the same time, CER 
calculated with total costs due to side effects treatment was practically equal (differ-
ence is 1,6% only). Cost prognosis for equal efﬁ cacy results with EL using is less by 
28,6% versus EX. The alternative scenario has conﬁ rmed the cinical-economic added 
value of EL. CONCLUSIONS: The change of original EL for generic EX in FOLFOX 
scheme for mCCR has no economic advantages. EL substitution leads to increased 
number of chemotherapy cycles, higher dose of oxaliplatin, higher rate of adverse 
effects, and higher costs.
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BACKGROUND: Colorectal cancer is the third leading cancer worldwide (INCA) 
with nearly 1.2 million cases and about 630,000 deaths expected in 2007 (ACS 2007). 
In Brazil, it is estimated 28,110 new cases in 2010 (INCA 2010). For patients with 
stage III colon cancer, the beneﬁ ts from ﬂ uorouracil (5-FU)-based adjuvant chemo-
